Every Form 4 that Zimmer Biomet (ZBH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZBH filings page.
Zimmer Biomet Holdings, Inc. senior vice president and chief human resources officer Lori Winkler reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 20, 2026, 1,845 RSUs were converted into 1,845 shares of common stock, and she received a new grant of 7,880 RSUs. According to the disclosure, each RSU represents a contingent right to receive one share of company common stock, and the new grant vests annually over three years in one-third increments starting February 20, 2027. The filing also shows 683 shares of common stock were withheld by the company at $98.62 per share to satisfy tax withholding obligations related to the RSU vesting.
Zimmer Biomet Holdings, Inc. reported that VP, Controller and Chief Accounting Officer Paul A. Stellato received new equity awards and related share movements. On February 20, 2026, he acquired 701 restricted stock units (RSUs) through an exercise or conversion and received additional RSU grants of 2,842 and 4,651 units at no cost. Each RSU represents a contingent right to one share of common stock, with one grant vesting annually over three years starting February 20, 2027, and the other vesting in full on February 20, 2028.
The 701 RSUs were converted into 701 shares of common stock, increasing his direct common stock holdings before tax withholding. To cover tax obligations on the RSU vesting, 362 common shares were withheld by the company at a price of $98.62 per share, leaving him with 4,109 common shares directly held, which includes 60 shares previously acquired under the Employee Stock Purchase Plan.
Zimmer Biomet Holdings, Inc. Chairman, President and CEO Ivan Tornos reported equity award and related share movements. He acquired 15,996 shares of common stock through the exercise of restricted stock units and received a new grant of 65,103 restricted stock units, each representing one future share of common stock.
To cover tax withholding on the RSU vesting, 8,846 common shares were withheld by the company at a price of $98.62 per share, a tax-withholding disposition rather than an open-market sale. After these transactions, Tornos directly owned 59,149 shares of common stock, which include 246 shares acquired under the Employee Stock Purchase Plan, and 65,103 restricted stock units that vest in three equal annual installments starting February 20, 2027.
Zimmer Biomet Holdings, Inc. executive vice president and CFO Suketu Upadhyay reported equity compensation activity involving restricted stock units (RSUs) and common stock. He received a grant of 21,701 RSUs, each representing a contingent right to one share of Zimmer Biomet common stock, vesting annually over three years in one-third increments starting February 20, 2027.
On the same date, 5,445 RSUs were converted into 5,445 shares of common stock through an exercise or conversion transaction. Of those shares, 2,446 were withheld by the company at a price of $98.62 per share to satisfy tax withholding obligations tied to the RSU vesting. Following these transactions, Upadhyay directly owned 57,753 shares of common stock.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported an equity compensation award tied to past performance. She acquired 3,935 performance-based restricted stock units, each representing one share of common stock, following a determination on February 19, 2026 of results for the 2023–2025 performance period. These 3,935 RSUs will vest on March 6, 2026, subject to the award’s terms.
Zimmer Biomet Holdings reported that Group President, EMEA, Wilfred Van Zuilen acquired 4,843 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock. These RSUs were earned based on performance for the 2023–2025 period, as determined on February 19, 2026, and are scheduled to vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. executive vice president and CFO Suketu Upadhyay reported an acquisition of 10,217 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock at no purchase price.
The RSUs were originally granted as performance-based awards on March 6, 2023, with results tied to a performance period covering 2023 to 2025. Based on actual performance determined on February 19, 2026, 10,217 RSUs were earned and are scheduled to vest on March 6, 2026, if vesting conditions are satisfied.
ZIMMER BIOMET HOLDINGS, INC. reported that executive Paul A. Stellato, its VP, Controller and Chief Accounting Officer, acquired 1,363 restricted stock units as part of a performance-based equity award. These RSUs were earned based on performance for the 2023–2025 period and are scheduled to vest on March 6, 2026.
Zimmer Biomet Holdings senior vice president and chief legal officer Chad F. Phipps reported an equity award tied to past performance. He acquired 4,692 restricted stock units as of February 19, 2026, at a stated price of $0.00 per unit. These RSUs were earned under a performance-based grant covering the 2023–2025 period and are scheduled to vest on March 6, 2026. Each RSU represents the right to receive one share of Zimmer Biomet common stock.
Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit. These RSUs were earned from performance-based awards granted in March and September 2023 for the 2023–2025 performance period.
Based on actual performance determined on February 19, 2026, Yi Sang earned 5,298 RSUs from the March 2023 grant and 1,752 RSUs from the September 2023 grant. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and the 7,050 RSUs will vest on March 6, 2026.
ZIMMER BIOMET HOLDINGS, INC. Chairman, President and CEO Ivan Tornos reported an acquisition of 24,436 restricted stock units (RSUs) tied to prior performance-based awards. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock at no purchase price.
The RSUs relate to performance-based grants awarded in March and September 2023 for a 2023–2025 performance period. Based on actual performance determined on February 19, 2026, he earned 12,184 RSUs from the March grant and 12,252 RSUs from the September grant, which together will vest on March 6, 2026 if conditions are satisfied.
Yi Sang reported open-market sale transactions in a Form 4 filing for ZBH. The filing lists transactions totaling 1,000 shares at a weighted average price of $96.49 per share. Following the reported transactions, holdings were 17,670 shares.
Zimmer Biomet Holdings, Inc. director Louis Shapiro reported a routine equity-related transaction involving deferred compensation. On 12/31/2025, he acquired 152.22 phantom stock units tied to Zimmer Biomet common stock under the company’s Deferred Compensation Plan for Non-Employee Directors. Each unit is convertible into one share of common stock, and the units are scheduled to be settled in company shares within sixty days after he ceases serving as a director. Following this transaction, he beneficially owned 2,500.354 phantom stock units, which includes 5.625 units previously accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Arthur J. Higgins reported changes in his deferred compensation holdings. On 12/31/2025 he acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors, which are tied 1-for-1 to shares of common stock. These units are scheduled to be settled in cash in ten annual installments after his service as a director ends, beginning within sixty days after the end of the calendar year in which his board service ceases.
Following this transaction, Higgins beneficially owned 35,967.099 phantom stock units. This total includes 85.437 phantom stock units that were previously accrued on October 31, 2025 under the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Theresa Maria Hilado reported a change in her deferred compensation holdings tied to company stock. On 12/31/2025 she acquired 373.63 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 conversion rate with common stock. Following this transaction, she beneficially owned 11,275.465 phantom stock units.
The phantom stock units are to be settled in cash in ten annual installments, beginning within sixty days after the end of the calendar year in which her service as a director ends. The reported balance includes 26.117 phantom units accrued on 10/31/2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings, Inc. director Devdatt Kurdikar reported an equity-related transaction on 12/31/2025 under a deferred compensation arrangement. The filing shows the acquisition of 152.22 phantom stock units at a listed conversion or exercise price of $90.33, bringing his total directly held phantom stock units to 1,769.983.
The units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and are designed to be settled in shares of Zimmer Biomet common stock on a 1-for-1 basis within sixty days after he ceases serving as a director. The total includes 3.876 phantom stock units that were added on October 31, 2025 through the plan’s dividend reinvestment provision.
Zimmer Biomet Holdings director reports phantom stock unit grant. On 12/31/2025, a company director acquired 172.977 phantom stock units under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. These units are tied 1-for-1 to shares of Zimmer Biomet common stock and are scheduled to be settled in company shares within sixty days after the director’s service on the board ends. Following this transaction, the director beneficially owned a total of 5,579.523 phantom stock units, which includes 12.952 units accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings, Inc. reported a director-level deferred compensation transaction involving phantom stock units. On 12/31/2025, a director acquired 304.439 phantom stock units under the company’s Deferred Compensation Plan for Non-Employee Directors at a 1-for-1 ratio with common stock.
After this transaction, the director beneficially owned 31,586.952 phantom stock units in total. These units are to be settled in cash in five annual installments, beginning within sixty days after the end of the calendar year in which the director’s service on the board ends. The total includes 74.943 phantom stock units that were accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings, Inc. director Michael J. Farrell reported a deferred compensation transaction involving phantom stock units as of 12/31/2025. He acquired 415.144 phantom stock units tied to Zimmer Biomet common stock under the company's Deferred Compensation Plan for Non-Employee Directors at a stated conversion rate of 1-for-1. Each unit represents the economic value of one share, but the units are to be settled in cash, in a lump sum, within sixty days after he ceases serving as a director. Following this transaction, he holds 17,775.682 phantom stock units directly, which includes 41.590 units that were previously accrued on 10/31/2025 through the plan’s dividend reinvestment feature.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported routine equity compensation activity involving restricted stock units (RSUs) tied to the company’s common stock. On 11/28/2025, RSUs covering 56.534 shares and 122.695 shares were settled into common stock at an exercise price of $0 per share, reflecting previously granted awards becoming deliverable. On the same date, 56.534 shares and 122.695 shares of common stock were withheld at a price of $97.52 per share to cover FICA and related tax obligations associated with her retirement eligibility under the terms of those awards. Following these transactions, she directly holds 6,833 shares of common stock, along with remaining RSUs that vest on March 6, 2026, and in two tranches on February 20, 2026 and February 20, 2027.
Zimmer Biomet Holdings (ZBH) reported an insider equity transaction by its Exec VP & CFO, Suketu Upadhyay. On November 10, 2025, 10,632 performance-based RSUs vested and were converted into common stock at $0 per share. To cover taxes, 4,731 shares were withheld at a price of $87.73 per share.
Following these transactions, the executive’s directly held common stock totaled 54,754 shares. The filing notes these RSUs each represented the right to receive one share of common stock, and the earned performance-based RSUs vested on November 10, 2025.
Zimmer Biomet Holdings (ZBH) reported an insider equity award on a Form 4. The company’s Executive Vice President and CFO received 10,632 restricted stock units (RSUs), recorded as an acquisition at $0 per unit and held directly.
The RSUs were part of a performance-based grant made on September 1, 2023, with results measured over October 1, 2024 to September 30, 2025. On October 24, 2025, the final outcome was determined, and 10,632 RSUs were earned. Each RSU represents the right to receive one share of Zimmer Biomet common stock. The earned RSUs are scheduled to vest on November 10, 2025.
Devdatt Kurdikar, a Director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 140.163 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The derivative units convert on a 1-for-1 basis into common stock and are scheduled to be settled in shares within sixty days after the director’s service ends. The report shows 1,613.887 shares of common stock beneficially owned following the reported transaction, and it notes 3.428 phantom units were added on 07/31/2025 via the plan’s dividend reinvestment provision.
Kolli Sreelakshmi, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported on Form 4 that 159.276 phantom stock units were acquired on 09/30/2025 under the company’s Deferred Compensation Plan for Non-Employee Directors. The units convert 1-for-1 into common shares and are to be settled in company stock within sixty days after the director stops service. Following the transaction, the report shows beneficial ownership of 5,393.594 shares (including 13.119 units added via dividend reinvestment on 07/31/2025). The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Maria Teresa Hilado, a director of Zimmer Biomet Holdings, Inc. (ZBH), reported an acquisition of 344.036 phantom stock units on 09/30/2025 under the companys Deferred Compensation Plan for Non-Employee Directors. The phantom units convert 1-for-1 into common stock value and are to be settled in cash in ten annual installments commencing within 60 days after the end of the calendar year in which her director service ends. The report notes 26.33 of the units were credited on 07/31/2025 via the plans dividend reinvestment provision. Following the transaction the filing shows total beneficial ownership of 10,875.718 shares.
Robert Hagemann, a non-employee director of Zimmer Biomet Holdings, Inc. (ZBH), was granted 280.326 phantom stock units on 09/30/2025 under the company's Deferred Compensation Plan for Non-Employee Directors. The units convert on a 1-for-1 basis into common stock value and are recorded at a per-unit price of $98.1, producing a reported aggregate value of $31,207.57. The filing notes that 79.18 of the units were accrued on 07/31/2025 under a dividend reinvestment provision. The phantom units are payable in cash in five annual installments beginning within 60 days after the calendar year in which the director's service ends.
Insider transaction disclosed for ZIMMER BIOMET HOLDINGS, INC. (ZBH). The reporting person, Sang Yi, Group President, Asia Pacific and an officer and director, reported a sale of 1,200 shares of common stock on 09/11/2025 at a price of $103.585 per share. After the sale, the filing shows 18,584 shares beneficially owned by the reporting person. The filing also notes that the reported beneficial ownership includes 160 shares acquired under the Employee Stock Purchase Plan on June 30, 2025. The Form 4 was signed by an attorney-in-fact on 09/15/2025.